Conclusions: Dietary habits, by increasing the percentage of intestinal Gram-negative endotoxin

producers, may accelerate liver fibrogenesis, introducing dysbiosis as a cofactor contributing to chronic liver injury in NAFLD. (Hepatology 2014;59:1738–1749) “
“Welzel et al.1 found that preexisting metabolic syndrome conferred a statistically significant increase of primary liver cancers that was independent of other risk factors. We suggest that this pathological association may partially be related to the higher body iron stores often found in such patients. A wealth of evidence has established a link between serum ferritin, insulin resistance, and nonalcoholic fatty liver disease (NAFLD). Body iron excess has frequently been found in patients with metabolic R428 solubility dmso syndrome.2 Furthermore, it has been suggested that the relation between serum ferritin and most of metabolic syndrome features might be mediated by the presence of NAFLD at the population-based

level.3 Excessive hepatic iron accumulation in NAFLD can be one of the potential cofactors involved in enhanced oxidative stress, which triggers liver cell necrosis and activation of hepatic stellate cells, both of which lead to fibrosis.4 Indeed, iron depletion by phlebotomy was found to be beneficial in improving insulin resistance in patients with NAFLD and hyperferritinemia.5 On the other hand, it has been shown that individuals with excess total body iron have a higher risk of liver cancer even in the absence of genetic Selleck DAPT hemochromatosis.6 Interestingly, iron depletion therapy with both phlebotomies and a low-iron diet was shown to significantly lower the risk of hepatocellular carcinoma in patients with

chronic hepatitis C.7 Therefore, we hypothesize that iron, metabolic syndrome, NAFLD, and liver cancer may be linked together, and their risk might be modified in parallel by maneuvers that affect either feature. Luca Mascitelli M.D.*, Mark R. Goldstein M.D., FACP†, * Medical Service, Comando Brigata Alpina “Julia”, Udine, Italy, † Fountain Medical Court, Bonita Springs, FL. “
“Background and Aims:  We evaluated the prognosis and associated factors in patients with small hepatocellular carcinoma (HCC; up to 3 nodules, each up to 3cm in diameter) treated with percutaneous 上海皓元医药股份有限公司 radiofrequency ablation (RFA) as first-line treatment. Methods:  Eighty-eight consecutive patients who underwent percutaneous RFA as first-line treatment were enrolled, among whom 70 who had hypervascular HCC nodules which were treated by a combination of transcatheter arterial chemoembolization and RFA. RFA was repeated until an ablative margin was obtained. Results:  The rate of local tumor progression at 1 and 3 years was 4.8% and 4.8%, respectively. The rate of overall survival at 3 and 5 years was 83.0% and 70.